Nearly 40% of all gastric cancers (GCs) have genetic alterations in at least one of the FGFR2, KRAS, EGFR, ERBB2, and MET signaling axes and FGFR2 is the most frequently amplified component [9]. Here, FGFR2 is linked to gastric cancer.